MRNS News
Archived Headlines
- 22 US IPOs planned for the week of Jul 28 07/28/14
- Epilepsy biotech Marinus Pharmaceuticals sets terms for $52 million IPO 07/18/14
- Biotech Sage Therapeutics files for a $69 million IPO to fund treatments for deadly seizures 06/17/14
- Epilepsy biotech Marinus Pharmaceuticals files for a $63 million IPO 05/12/14
Epilepsy device maker NeuroSigma sets terms for $50 million IPO
NeuroSigma, which develops electrical devices used to treat drug-resistant epilepsy and depression, announced terms for its IPO on Monday. The Los Angeles, CA-based company plans to raise $50 million by offering 3.6 million shares at a price range of $13 to $15....read more
Epilepsy device maker NeuroSigma files for a $50 million IPO
NeuroSigma, which develops electrical devices used to treat drug-resistant epilepsy and depression, filed on Tuesday with the SEC to raise up to $50 million in an initial public offering. The company is in pivotal trials to have its bioelectronic products...read more
US IPO Pricing Recap: 15 IPOs in the most active week since 2007; 66% ended at or below IPO price
15 companies had initial public offerings and raised $6.4 billion this week, making it the most active week in the IPO market since 2007. Including deals that priced yesterday and began trading today, July saw 34 IPOs, a post-tech bubble record....read more
Marinus Pharmaceuticals prices IPO at $8, well below the $12-$14 range
Marinus Pharmaceuticals, an early-stage biotech developing an add-on therapy for epilepsy, raised $45 million by offering 5.6 million shares at $8, well below the $12-$14 range. Marinus Pharmaceuticals will list on the NASDAQ under the symbol MRNS. Marinus...read more